The Multiple Odysseys in Research and Clinical Care for Neurogenetic Conditions.
Get your caregiver supports and family-centered outcome tools in place before gene therapy hits the clinic.
01Research in Context
What this study did
Stern (2024) wrote a story-style review. The paper lists what services must get ready before gene therapy trials start.
It focuses on people with intellectual or developmental disabilities caused by rare gene changes.
The author did not run new experiments. Instead, the paper gathers expert views and past reports.
What they found
No numbers are given. The review says clinics must build two things now.
First, strong caregiver support. Second, outcome tools that matter to families, not just doctors.
These steps will matter when gene therapies leave the lab and enter real clinics.
How this fits with other research
Dall et al. (1997) asked for the same fixes 27 years ago. They wanted better services and staff training for people with ID. Stern (2024) repeats the call, but adds the new reason of gene therapy.
Schaaf et al. (2015) give hard data that backs the plan. Their survey showed teachers know little about syndromes like Fragile X or Prader-Willi. The 2024 paper says we must fix that knowledge gap before gene therapy arrives.
Donahoe et al. (2000) warned that autism services had system and cost problems. Stern (2024) widens the warning to all neurogenetic conditions and ties it to future gene treatments.
Why it matters
You may soon meet families asking about gene therapy. This paper tells you to get ready now. Start using outcome measures that track daily life, not just IQ scores. Add caregiver support goals to every plan. These small shifts will align your practice with the treatments heading our way.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Pick one daily-living skill that matters to your client’s family and add it as a tracked goal this week.
02At a glance
03Original abstract
Neurogenetic conditions (NGC; e.g., fragile X, Angelman, Prader-Willi syndromes) represent the cause for intellectual or developmental disabilities in up to 60% of cases. With expanded diagnostic options and an increasing focus on the development of gene therapies comes the potential of improved quality of life for individuals with NGCs and their families. However, these emerging initiatives also bring new challenges and considerations for NGC researchers and clinicians, including considerations for supporting caregivers and assuring outcome measures for clinical trials adequately reflect the lived experiences of people with NGCs. This paper summarizes the advances and current and future challenges of research and clinical service provision for people with NGCs and their caregivers.
American journal on intellectual and developmental disabilities, 2024 · doi:10.1352/1944-7558-129.2.110